Phosphorylation of cardiac myosin binding protein-C (cMyBP-C) is a regulator of pump function in healthy hearts. However, the mechanisms of regulation by cAMP-dependent protein kinase (PKA)-mediated cMyBP-C phosphorylation have not been completely dissociated from other myofilament substrates for PKA, especially cardiac troponin I (cTnI). We have used synchrotron X-ray diffraction in skinned trabeculae to elucidate the roles of cMyBP-C and cTnI phosphorylation in myocardial inotropy and lusitropy. Myocardium in this study was isolated from four transgenic mouse lines in which the phosphorylation state of either cMyBP-C or cTnI was constitutively altered by site-specific mutagenesis. Analysis of peak intensities in X-ray diffraction patterns from trabeculae showed that cross-bridges are displaced similarly from the thick filament and toward actin (1) when both cMyBP-C and cTnI are phosphorylated, (2) when only cMyBP-C is phosphorylated, and (3) when cMyBP-C phosphorylation is mimicked by replacement with negative charge in its PKA sites. These findings suggest that phosphorylation of cMyBP-C relieves a constraint on cross-bridges, thereby increasing the proximity of myosin to binding sites on actin. Measurements of Ca(2+)-activated force in myocardium defined distinct molecular effects due to phosphorylation of cMyBP-C or co-phosphorylation with cTnI. Echocardiography revealed that mimicking the charge of cMyBP-C phosphorylation protects hearts from hypertrophy and systolic dysfunction that develops with constitutive dephosphorylation or genetic ablation, underscoring the importance of cMyBP-C phosphorylation for proper pump function.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472100PMC
http://dx.doi.org/10.1016/j.yjmcc.2012.07.012DOI Listing

Publication Analysis

Top Keywords

cmybp-c phosphorylation
16
myosin binding
12
cmybp-c ctni
12
cmybp-c
11
phosphorylation
10
binding protein-c
8
protein kinase
8
thick filament
8
pump function
8
x-ray diffraction
8

Similar Publications

Heart failure with preserved ejection fraction (HFpEF) is a major public health challenge, affecting millions worldwide and placing a significant burden on healthcare systems due to high hospitalization rates and limited treatment options. HFpEF is characterized by impaired cardiac relaxation, or diastolic dysfunction. However, there are no therapies that directly treat the primary feature of the disease.

View Article and Find Full Text PDF

D389V Variant Induces Hypercontractility in Cardiac Organoids.

Cells

November 2024

Center for Cardiovascular Research, Division of Cardiovascular Health and Disease, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.

, encoding cardiac myosin binding protein-C (cMyBP-C), is the most mutated gene known to cause hypertrophic cardiomyopathy (HCM). However, since little is known about the underlying etiology, additional in vitro studies are crucial to defining the underlying molecular mechanisms. Accordingly, this study aimed to investigate the molecular mechanisms underlying the pathogenesis of HCM associated with a polymorphic variant (D389V) in by using isogenic human-induced pluripotent stem cell (hiPSC)-derived cardiac organoids (hCOs).

View Article and Find Full Text PDF

Early pathological mechanisms in a mouse model of heart failure with preserved ejection fraction.

Am J Physiol Heart Circ Physiol

December 2024

Department of Internal Medicine/Cardiology, Rush University Medical Center, Chicago, Illinois, United States.

Article Synopsis
  • Heart failure with preserved ejection fraction (HFpEF) is a prevalent condition but lacks effective treatments, prompting a study to investigate its underlying causes using a mouse model exposed to a Western diet and excess mineralocorticoids.
  • The study found early signs of cardiac issues such as diastolic dysfunction and left atrial enlargement within three weeks, even though heart ejection fraction remained normal.
  • Molecular analysis revealed low-grade inflammation, oxidative stress, and impaired signaling pathways affecting heart stiffness and function, possibly linking dietary factors and mineralocorticoids to the progression of HFpEF.
View Article and Find Full Text PDF

Roles of cMyBP-C phosphorylation on cardiac contractile dysfunction in mice.

J Mol Cell Cardiol Plus

June 2024

Center for Cardiovascular Research, Department of Internal Medicine, Division of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.

Type 2 diabetes mellitus (T2DM) is a metabolic disease and comorbidity associated with several conditions, including cardiac dysfunction leading to heart failure with preserved ejection fraction (HFpEF), in turn resulting in T2DM-induced cardiomyopathy (T2DM-CM). However, the molecular mechanisms underlying the development of T2DM-CM are poorly understood. It is hypothesized that molecular alterations in myopathic genes induced by diabetes promote the development of HFpEF, whereas cardiac myosin inhibitors can rescue the resultant T2DM-mediated cardiomyopathy.

View Article and Find Full Text PDF

Phosphorylation of cardiac myosin binding protein-C (cMyBP-C) is a determinant of cardiac myofilament function. Although cMyBP-C phosphorylation by various protein kinases has been extensively studied, the influence of protein phosphatases on cMyBP-C's multiple phosphorylation sites has remained largely obscure. Here we provide a detailed biochemical characterization of cMyBP-C dephosphorylation by protein phosphatases 1 and 2 A (PP1 and PP2A), and develop an integrated kinetic model for cMyBP-C phosphorylation using data for both PP1, PP2A and various protein kinases known to phosphorylate cMyBP-C.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!